Paul Capital Partners

Paul Capital Partners, established in 1991, is a global investment firm specializing in the secondary market of private equity. With nearly 100 employees across offices in Hong Kong, London, New York, Paris, San Francisco, and São Paulo, the firm manages over $6 billion. Paul Capital provides creative liquidity solutions to institutional investors, offering early exits from private equity limited partnerships and direct investment portfolios. Additionally, the firm's Healthcare Platform invests in royalty and revenue interests in life science products. Paul Capital serves a diverse range of clients, including pension plans, financial institutions, endowments, family offices, corporations, and general partners.

Richard Chow

Principal

Phil Jensen

Partner and CFO

Jonathan Kelemen

Associate

Ken Macleod

Partner

Guillaume Partiols

Principal and Managing Director, Secondary Private Equity

Marion Peiridier

Senior Associate

Bryon Sheets

Partner

Elaine Small

Partner

Brian Sullivan

Partner

Debbie Wong

Executive Director, Management Company

Lucian Wu

Managing Director

12 past transactions

Carbon Black

Venture Round in 2011
Carbon Black, Inc. is a cybersecurity company that offers advanced security solutions to clients in the United States and internationally. Founded in 2002 and headquartered in Waltham, Massachusetts, the company provides a comprehensive platform known as the Cb Predictive Security Cloud, which leverages big data and analytics to enhance endpoint security. Carbon Black's suite of products includes endpoint detection and response solutions, antivirus software, threat hunting services, and real-time security operations capabilities. Its offerings help organizations predict, prevent, detect, respond to, and remediate cyber threats, including malware and ransomware attacks. The company serves a diverse clientele, including security-focused enterprises, government agencies, and small to mid-sized organizations. In January 2016, Carbon Black changed its name from Bit9, Inc. and has since established itself as a leader in the cybersecurity industry, providing innovative solutions to protect critical systems and data. As of October 2019, Carbon Black operates as a subsidiary of VMware, Inc.

Recyclebank

Series C in 2011
Recyclebank is a company dedicated to promoting sustainable living by incentivizing individuals for their eco-friendly actions. Through its platform, Recyclebank engages users in environmental awareness by offering rewards, such as discounts and deals from various local and national businesses, for completing specific challenges related to recycling and sustainability. By encouraging participation in green initiatives, Recyclebank aims to foster a culture of sustainability, helping individuals and communities realize the importance of reducing waste and increasing recycling rates.

Tethys BioScience

Venture Round in 2010
Tethys BioScience, Inc. is focused on the discovery, development, and commercialization of biological markers for diagnosing metabolic diseases, particularly diabetes. The company has developed the PreDx Diabetes Risk Test, which evaluates a combination of proteins and other blood-borne biomarkers associated with diabetes risk. Founded in 2002, Tethys BioScience is headquartered in Emeryville, California.

Phase III Development

Private Equity Round in 2010
Phase III Development is a Software Engineering company with expertise in a wide variety of development technologies. The mission is to provide customers with innovative custom software solutions of superior quality. They deliver on budget and on time.

UCB

Post in 2009
UCB SA, established in 1928, is a Belgium-based biopharmaceutical company that develops and markets therapies for neurology and immunology diseases. Its primary products include Cimzia for inflammatory diseases, Vimpat and Briviact for epilepsy, Neupro for Parkinson's disease and restless legs syndrome, and Nayzilam for seizure clusters. Additionally, UCB offers treatments for allergies, memory problems, narcolepsy, and osteoporosis. The company is also involved in developing novel therapies for conditions like myasthenia gravis, drug-resistant epilepsy, and systemic lupus erythematosus. UCB engages in research and development activities in neurology, immunology, and other areas, and has collaboration agreements with several pharmaceutical companies.

SpePharm

Venture Round in 2008
SpePharm is a European specialty pharmaceutical company focused on acquiring, registering, and marketing high-value medicines primarily for the hospital market. The company specializes in oncology, hematology, and supportive care, offering medical products that assist clinicians in managing oral complications associated with radiotherapy or chemotherapy. SpePharm's management team possesses extensive global experience in the pharmaceutical sector, particularly with a deep understanding of the European regulatory landscape and the nuances of niche and orphan products. Their expertise allows them to implement innovative strategies and achieve notable successes in the field.

On-X Life Technologies

Venture Round in 2007
On-X Life Technologies Inc. specializes in the development, manufacturing, and marketing of artificial heart valve replacement and repair products. The company's diverse product portfolio includes aortic and mitral heart valves equipped with standard, anatomic, and Conform-X sewing rings, as well as ascending aortic prostheses and chordal repair products. Additionally, On-X offers cardiovascular specialty products and provides technical services related to carbon-based technology, encompassing medical design, product development, and manufacturing. Founded in 1994 and based in Austin, Texas, the company was previously known as Medical Carbon Research Institute and rebranded in 2007. As of January 2016, On-X operates as a subsidiary of CryoLife Inc.

Acorda Therapeutics

Post in 2006
Acorda Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders. Founded in 1995 and headquartered in Ardsley, New York, the company markets Ampyra (dalfampridine), an oral drug approved by the FDA to improve walking in patients with multiple sclerosis (MS). In Europe, this drug is marketed as Fampyra. Acorda also markets Selincro for alcohol dependence in Europe and Zanaflex Capsules for spasticity management. Additionally, the company develops Inbrija for treating OFF periods in Parkinson’s disease and ARCUS for acute migraine. Other pipeline products include rHIgM22 for MS and Cimaglermin alfa for heart failure. Acorda has collaborations with Biogen Inc. for Ampyra's development and commercialization.

Prism Pharmaceuticals

Series B in 2006
Prism Pharmaceuticals, Inc. is an acute care pharmaceutical company based in King of Prussia, Pennsylvania, founded in 2004. The company specializes in the development and commercialization of cardiovascular injectable products specifically for the United States market. Its notable offerings include NEXTERONE, an injectable antiarrhythmic agent, and PM103, an intravenous formulation of clopidogrel bisulfate.

Verus Pharmaceuticals

Series A in 2005
Verus Pharmaceuticals is a pediatric-oriented company that identifies, develops, and delivers solutions to address the unmet medical needs of children and those who care for them. It offers treatment of asthma, allergies, and related diseases and conditions. The company also offers Twinject, an epinephrine auto-injector for anaphylaxis. Verus Pharmaceuticals is based in San Diego, California.

ROXY.com

Private Equity Round in 2000
Roxy is a female sports fashion clothing brand based in Costa Mesa, California, specializing in a variety of apparel and accessories. The brand offers an extensive online shop where customers can purchase clothing items such as dresses, tops, tees, tanks, hoodies, jackets, and loungewear, as well as swimwear, shoes, and a range of accessories including handbags, backpacks, hats, and gloves. Roxy focuses on providing a diverse selection of products to meet the needs and budgets of its customers, catering to those interested in sports and active lifestyles.

eVentures Group

Venture Round in 2000
eVentures Group operates and invests in internet communications companies.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.